EDX EDX Medical Group Plc

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended.  On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

18 February 2025

EDX Medical Group plc

AQSE: EDX

("EDX Medical" or the "Group" or "Company")

DIRECTOR DEALING

CAMBRIDGE, UK: EDX Medical Group, plc ("EDX Medical", the "Company" or the "Group"), which develops innovative digital diagnostic products and services for the personalised treatment for cancer, heart disease and infectious diseases, today announces that Dr Michael Hudson, chief executive officer of the Company, purchased a total of 45,888 ordinary shares in the Company on February 17, 2025, at a price per share of 10.87 pence.

The Company also announces that Martin Walton, board director and deputy chair of the Group, purchased a total of 85,000 ordinary shares in the Company on February 17, 2025, at an average price per share of 10.717 pence.

Following these purchases, Dr Hudson owns 20,445,888 ordinary shares, representing 5.84% of the issued share capital.

Mr Walton owns 85,000 ordinary shares, representing 0.02% of the issued share capital.

The directors of the Company accept responsibility for the contents of this announcement.

ENDS

Contacts

Notes for Editors:

About EDX Medical Group plc

The EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease in order to personalise treatment in a timely fashion. Early disease detection and biologically-based personal treatment optimisation is considered to be the most impactful way of reducing deaths and lowering the cost of healthcare globally.

EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has a number of significant strategic partnerships including; a product technology collaboration with Thermo Fisher EMEA Ltd, a logistics partnership with Fedex and a distribution agreement with Caris Life Sciences inc, each world leaders in their respective fields.

www.edxmedical.com